Concepts (87)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pancreatic Neoplasms | 7 | 2024 | 332 | 1.080 |
Why?
|
| Pancreatic Fistula | 1 | 2024 | 18 | 0.910 |
Why?
|
| Pancreatectomy | 1 | 2024 | 97 | 0.870 |
Why?
|
| Surgical Flaps | 1 | 2024 | 113 | 0.820 |
Why?
|
| Robotic Surgical Procedures | 1 | 2024 | 130 | 0.760 |
Why?
|
| Postoperative Complications | 3 | 2024 | 1217 | 0.710 |
Why?
|
| Pyrimidinones | 3 | 2016 | 15 | 0.690 |
Why?
|
| Pyridones | 3 | 2016 | 37 | 0.670 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2014 | 208 | 0.410 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2014 | 218 | 0.390 |
Why?
|
| Antibodies, Monoclonal | 1 | 2014 | 837 | 0.330 |
Why?
|
| Antineoplastic Agents | 2 | 2014 | 632 | 0.330 |
Why?
|
| Carcinoma, Pancreatic Ductal | 3 | 2016 | 106 | 0.250 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2016 | 170 | 0.240 |
Why?
|
| ErbB Receptors | 2 | 2014 | 113 | 0.210 |
Why?
|
| Adenocarcinoma | 2 | 2024 | 327 | 0.200 |
Why?
|
| Liver Neoplasms | 2 | 2016 | 277 | 0.200 |
Why?
|
| Gene Expression Profiling | 2 | 2014 | 727 | 0.180 |
Why?
|
| Caregivers | 1 | 2021 | 233 | 0.150 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2016 | 179 | 0.140 |
Why?
|
| Receptor, ErbB-2 | 2 | 2014 | 49 | 0.140 |
Why?
|
| Mutation | 2 | 2014 | 2462 | 0.130 |
Why?
|
| Retrospective Studies | 3 | 2024 | 6153 | 0.130 |
Why?
|
| Hemangioma | 1 | 2015 | 28 | 0.120 |
Why?
|
| Hepatectomy | 1 | 2015 | 62 | 0.120 |
Why?
|
| Adenoma | 1 | 2015 | 65 | 0.120 |
Why?
|
| Phosphorylation | 2 | 2014 | 886 | 0.120 |
Why?
|
| Pancreaticoduodenectomy | 1 | 2015 | 63 | 0.120 |
Why?
|
| Trastuzumab | 1 | 2014 | 11 | 0.110 |
Why?
|
| Genes, Neoplasm | 1 | 2014 | 24 | 0.110 |
Why?
|
| Precancerous Conditions | 1 | 2015 | 70 | 0.110 |
Why?
|
| Tumor Burden | 1 | 2014 | 61 | 0.110 |
Why?
|
| Cholangiocarcinoma | 1 | 2014 | 28 | 0.110 |
Why?
|
| Bile Duct Neoplasms | 1 | 2014 | 43 | 0.110 |
Why?
|
| Aged | 4 | 2024 | 13510 | 0.110 |
Why?
|
| Cell Line, Tumor | 2 | 2014 | 1380 | 0.100 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2014 | 191 | 0.100 |
Why?
|
| Male | 5 | 2024 | 27952 | 0.100 |
Why?
|
| Quinazolines | 1 | 2013 | 22 | 0.100 |
Why?
|
| Drug Therapy, Combination | 1 | 2014 | 452 | 0.100 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2014 | 305 | 0.100 |
Why?
|
| Middle Aged | 4 | 2024 | 16449 | 0.100 |
Why?
|
| Humans | 10 | 2024 | 59737 | 0.100 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2014 | 482 | 0.090 |
Why?
|
| Genomics | 1 | 2014 | 322 | 0.090 |
Why?
|
| Biomarkers, Tumor | 1 | 2014 | 466 | 0.090 |
Why?
|
| Neoplasms | 1 | 2021 | 1238 | 0.090 |
Why?
|
| Signal Transduction | 3 | 2014 | 2905 | 0.080 |
Why?
|
| Adult | 2 | 2024 | 15771 | 0.080 |
Why?
|
| Female | 4 | 2024 | 30925 | 0.070 |
Why?
|
| Disease Models, Animal | 1 | 2014 | 2060 | 0.070 |
Why?
|
| Animals | 3 | 2016 | 19705 | 0.050 |
Why?
|
| Early Detection of Cancer | 1 | 2024 | 282 | 0.040 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2024 | 679 | 0.040 |
Why?
|
| Prognosis | 2 | 2014 | 1613 | 0.040 |
Why?
|
| Insurance, Health | 1 | 2021 | 144 | 0.040 |
Why?
|
| Hospitals | 1 | 2021 | 380 | 0.040 |
Why?
|
| Prospective Studies | 1 | 2024 | 3090 | 0.030 |
Why?
|
| Qualitative Research | 1 | 2021 | 620 | 0.030 |
Why?
|
| Quality of Health Care | 1 | 2021 | 514 | 0.030 |
Why?
|
| Cystadenoma | 1 | 2015 | 6 | 0.030 |
Why?
|
| Virginia | 1 | 2015 | 23 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 1 | 2016 | 453 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2024 | 2068 | 0.030 |
Why?
|
| Morbidity | 1 | 2015 | 113 | 0.030 |
Why?
|
| Bile Ducts, Intrahepatic | 1 | 2014 | 26 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2014 | 83 | 0.030 |
Why?
|
| Lymphatic Metastasis | 1 | 2014 | 75 | 0.030 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2014 | 193 | 0.030 |
Why?
|
| Lymph Nodes | 1 | 2014 | 215 | 0.030 |
Why?
|
| Neoplasm Invasiveness | 1 | 2014 | 262 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2014 | 357 | 0.030 |
Why?
|
| Up-Regulation | 1 | 2014 | 367 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2014 | 558 | 0.030 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2014 | 297 | 0.030 |
Why?
|
| Neoplasm Staging | 1 | 2014 | 454 | 0.030 |
Why?
|
| Neoplasm Transplantation | 1 | 2013 | 163 | 0.030 |
Why?
|
| MAP Kinase Kinase Kinases | 1 | 2013 | 74 | 0.020 |
Why?
|
| MAP Kinase Signaling System | 1 | 2013 | 203 | 0.020 |
Why?
|
| Mice | 2 | 2016 | 10316 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2014 | 1570 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2015 | 2387 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2014 | 2354 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2015 | 5147 | 0.020 |
Why?
|
| Young Adult | 1 | 2015 | 4290 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2015 | 5334 | 0.010 |
Why?
|
| Adolescent | 1 | 2015 | 5866 | 0.010 |
Why?
|